Hovione celebrates its 50th Anniversary this year. The celebrations of this important milestone will take place at the various plants of the Group, on the dates mentioned below. The program will be announced shortly. We remind you of the website that was created specially for the purpose, 50anos.hovione.com, which you can access and tell your story. We would like to hear from all those who have been linked to Hovione over the years. We are counting on your participation to help write the history of Hovione’s first 50 years.

Please save these dates on your calendar and sign up to participate in the celebrations.

 

Loures 17-19 September	New Jersey 22 and 23 September	Ireland 7 October	Macao 8 November	Taizhou 11 November

Hovione continues to exhibit rapid sales growth. To keep pace with increased sales, we have added new manufacturing locations (Cork, Ireland & Taizhou,China) and added to the headcount in our sales organization. Our expanded sales team will enable us to continue to provide the highest quality of service to our diversified global pharmaceutical customer base.

The European, Middle East and Asia zone is under the management of Roger Viney (rviney@hovione.com) and is organised as follows:
    - Pedro Rosado (prosado@hovione.com) manages our sales in Exclusives and Particle Design within Germany and Switzerland.
    - Antonio Denis (adinis@hovione.com) joins the sales team. Antonio is responsible for our Generics and Inhalation
      businesses in Germany, Switzerland and central Europe.
    - Edgar Alexandre (ealexandre@hovione.com) is responsible for the Middle East and Asia.
    - Luisa Ferreira (lferreira@hovione.com) manages our business in UK, Ireland, Netherlands, Belgium and Scandinavia.
    - Ana Geraldes (ageraldes@hovione.com) joins the team and is responsible for France, Italy, Spain and southern Europe.

The North America zone is under the management of Steve Beagle (sbeagle@hovione.com) and is organized as follows:
    - Laurie Seifert (lsiefert@hovione.com) manages key accounts and new opportunities for the Exclusives and Particle Design
      business units.
    - Matt Hanson (mhanson@hovione.com) manages key accounts and new opportunities for our Exclusives and Particle Design
      business units.
    - Courtney Smith (csmith@hovione.com) manages key accounts and new opportunities for the Generics business unit.
    - Kevin Draper (kdraper@hovione.com) has just joined our team from SAFC and manages key accounts and new business
      opportunities for our Exclusives and Particle Design business units in the Western region.

The long-acting neuraminidase inhibitor CS-8958, targeting avian flu, is currently starting Phase III trials in Asian territories and late Phase I trials in the US and the UK.
This drug product consists of a dry powder inhalation formulation, developed at Hovione, delivered with Hovione’s patented device TwinCaps® inhaler. Market approval is expected by March 2010 for Japan, Taiwan, Hong Kong and South Korea, as reported in Japanese media in attached image. Rival drugs Relenza (GSK) and Tamiflu (Roche) already on the market require twice-daily usage for five consequent days, while CS-8958 is taken via a one-time only inhalation, making this a much more competitive product, with enormous compliance and effectiveness advantages. The TwinCaps® inhaler was specifically developed by Hovione for the project and licensed to the consortium, to be used with the drug substance in the treatment of the H5N1 avian flu virus.

Hovione Loures, which has already been certified under ISO14001 since January 2007 for its environmental management, received from SGS ICS, last January, the OHSAS18001 certification for the system of health and safety management at its installations.

Last November, Hovione Loures received the environmental license in accordance with the European Directive concerning Integrated Pollution Prevention and Control (IPPC). The new license brings together in one document all the environmental requirements applicable to the installation, and is valid for 10 years.

The pre-registration phase for substances in compliance with the new European regulation REACH (Registration, Evaluation, Authorization and Restriction of Chemical substances) ended on December 1, 2008 and Hovione preregistered more than two hundred substances. Across Europe, about 150,000 substances were pre-registered by roughly 65,000 companies through the computer-based system Reach-IT. The objective of REACH is to developed the health and environment of the EU through developed information on the safety data sheets and the labeling of chemical products.

At the close of the first year of activity of the “Hovione Ambassadors”, the assessment of the initiative is very positive and promising. Contacts were established with the major schools of Portugal, where the ambassadors were able to create and develop personal ties, at the same time learning about what is being done in terms of research. As a result, four research projects were established with the Universities of Minho and Oporto and with the Instituto Superior Técnico (High Technical Institute). Simultaneously, Hovione held “Scientific Seminars” that allowed academic researchers to come to Hovione to present their works. Hovione aims to establish protocols of collaboration with at least 2 more universities and be recognized as “best employer”, attracting the best graduates from Portuguese universities.